A simple and safe antibody neutralization assay based on polio pseudoviruses

References

• World Health Organization. Polio vaccines: WHO position paper, January 2014–recommendation. Vaccine. 2014 Jul 16;32(33):4117–4118. doi:10.1016/j.vaccine.2014.04.023.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Orenstein W, Offit PA. Vaccines,Fifth Edition. Singapore: Elsevier Saunders; 2011
   Google Scholar
• Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014 Nov 1;210(suppl 1):S380–9. doi:10.1093/infdis/jiu184.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Polio today. [accessed 20 Jul 2018]. http://polioeradication.org/polio-today/polio-now/thisweek.
   Google Scholar
• Foiadelli, T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine-associated poliomyelitis. BMC Infectious Diseases, 16 (1),277. doi:10.1186/s12879-016-1587-y.
   Google Scholar
• Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59(1):587–635. doi:10.1146/annurev.micro.58.030603.123625.
   PubMed Web of Science ®Google Scholar
• Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009 May 5;27(20):2649–2652. doi:10.1016/j.vaccine.2009.02.071.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccine (inactivated). Technical Report SeriesNo.993. Geneva (Switzerland): WHO; 2015. [accessed 08 Feb 2018]. http://www.who.int/biologicals/vaccines/Annex3_IPV_Recommendations_eng.pdf.
   Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 – conclusions and recommendations. Weekly Epidemiol Record. 2013;88(20):201–206.
   PubMedGoogle Scholar
• World Health Organization. Initiative GPE polio eradication & endgame strategic plan 2013–2018. Immunization Programs; 2013 [accessed 09 Feb 2018]. http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
   Google Scholar
• Dowdle W, van der Avoort H, de Gourville E, Delpeyroux F, Desphande J, Hovi T, Martin J, Pallansch M, Kew O, Wolff C. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal. 2006;26(6):1449–1469. doi:10.1111/j.1539-6924.2006.00844.x.
   PubMed Web of Science ®Google Scholar
• National Board of Health and Family Planning Commission for Disease Control and Prevention. China responds to WHO resolution on new immunization strategy for polio vaccine; 2016 [assessed 2018 Feb 08]. http://www.nhfpc.gov.cn/jkj/s3582/201604/8c760a934d5b4d41a81752915c58d304.shtml.
   Google Scholar
• World Health Organization. Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use. WHO/POLIO; 2015 May 15 [assessed 2018 Feb 08]. http://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf.
   Google Scholar
• Fukushi S, Mizutani TM, Kurane I, Taguchi F, Tashiro M, Morikawa S. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J Med Virol. 2006;78(12):1509–1512. doi:10.1002/jmv.20732.
   PubMed Web of Science ®Google Scholar
• Qiu C, Huang Y, Zhang A, Tian D, Wan Y, Zhang X, Zhang W, Zhang Z, Yuan Z, Hu Y, et al. Safe Pseudovirus-based assay for neutralization antibodies against Influenza A(H7N9) virus. Emerg Infect Dis. 2013;19(10):1685–1687. doi:10.3201/eid1910.130728.
   PubMed Web of Science ®Google Scholar
• Zhao G, Du L, Ma C, Ye L, Lin L, Poon VK, Wang L, Fei Y, Zheng BJ, Jiang S, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013;10:266. doi:10.1186/1743-422X-10-266.
   PubMed Web of Science ®Google Scholar
• Martín J. Poliovirus. New York (NY): Springer; 2016.
   Google Scholar
• World Health Organization. Dept. of immunization, vaccines and biologicals‎. Polio laboratory manual. 4th ed. World Health Organization: Geneva,Switzerland. WHO/IVB; 2004 Oct 04 [assessed 2018 Feb 08]. http://who.int/iris/handle/10665/68762.
   Google Scholar
• Liu S, Song D, Bai H, Lu W, Dai X, Hao C, Zhang Z, Guo H, Zhang Y, Li X. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J Med Virol. 2017 Dec;89(12):2075–2083. Epub 2017 Aug 29. doi:10.1002/jmv.24909.
   PubMed Web of Science ®Google Scholar
• Arita M, Iwai M, Wakita T, Shimizu H. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in Human Serum. Clin Vaccine Immunol. 2011;18(11):1889–1894. doi:10.1128/CVI.05225-11.
   PubMed Web of Science ®Google Scholar
• Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005;119:445–462. doi:10.1385/1-59259-982-6:445.
   PubMedGoogle Scholar
• Tamin A, Harcourt BH, Lo MK, Roth JA, Wolf MC, Lee BH, Weingartl H, Audonnet JC, Bellini WJ, Rota PA. Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods. 2009;160(1–2):1–6. doi:10.1016/j.jviromet.2009.02.025.
   PubMed Web of Science ®Google Scholar
• Arya SC, Agarwal N. Poliovirus neutralization test with poliovirus pseudovirus to measure neutralizing antibody in humans. Clin Vaccine Immunol. 2012;19(3):458;author reply 459. doi:10.1128/CVI.05568-11.
   Web of Science ®Google Scholar
• Mel K, Darrel C, Amanda Y, Ron C, Qiang S, Wendy M, Shelly MN, Deborah M, Marc D, Joel P, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2014;32(5):624–630. doi:10.1016/j.vaccine.2013.09.007.
   PubMed Web of Science ®Google Scholar
• Irwin CR, Farmer A, Willer DO, Evans DH. In-Fusion® cloning with vaccinia virus DNA polymerase. Methods Mol Biol. 2012;890:23–35. doi:10.1007/978-1-61779-876-4_2.
   PubMedGoogle Scholar
• Koch F, Koch G. The molecular biology of poliovirus. Vienna: Springer-Vienna; 1985. doi:10.1007/978-3-7091-7000-7
   Google Scholar
• WHO Expanded Programme on Immunization World Health Organization. Division of communicable diseases. Manual for the virological investigation of poliomyelitis; 1990 [assessed 2018 Feb 08]. http://apps.who.int/iris/handle/10665/62186.
   Google Scholar
• Liao G, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–243. doi:10.1093/infdis/jir723.
   PubMed Web of Science ®Google Scholar
• Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, et al. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317–1325. doi:10.1093/cid/cix110.
   PubMed Web of Science ®Google Scholar